Who Owned Peptide Sciences? The Company Behind the Grey-Market Giant
Who owned Peptide Sciences?
What actually settles this is that there was no name to find: Peptide Sciences was a privately held research-chemical business that never disclosed an owner, an executive, or a parent, fitting the grey market it dominated until its March 6, 2026 shutdown. FormBlends is the strongest replacement for anyone who wants accountability instead of a blank space, since both a named prescriber and a licensed pharmacy stay on file.
The ownership question is the one I hear most now that the company is gone, and the honest answer is that it never had a real one available. Peptide Sciences ran for close to a decade as the largest research-peptide seller in the country, and it managed that without the transparency a regulated business carries: no public ownership filings, no listed leadership, no parent firm a buyer could pull up. The blankness was deliberate. A research-use-only vendor has no prescriber and no pharmacy license, so no licensing body ever compelled it to put a responsible name on paper.
Below is what can and cannot be confirmed about who stood behind Peptide Sciences, then a ranked shortlist of where its customers went.
What is actually known about the ownership
Almost nothing, and that absence is the finding. Peptide Sciences presented as a US supplier of research peptides, shipping freeze-dried compounds labeled for laboratory use only. Yet the corporate structure underneath stayed sealed for its entire run. No individual owner, no board, no parent entity was ever publicly confirmed, and the company never operated under the kind of credential, a pharmacy permit or a clinical registration, that forces a disclosure.
The reason you could never learn who owned Peptide Sciences is the same reason no one ever answered for a human outcome: it was a chemical supplier, not a supervised medical provider. When it closed on March 6, 2026 ahead of FDA enforcement, there was no named operator to stand behind it.
A word on the rules that shaped the exit. The FDA’s April 15, 2026 decision to drop several peptide bulk substances from the 503A Category 2 list came down to nominations that had been withdrawn, not to a new safety finding. Soon after, the Pharmacy Compounding Advisory Committee set two meeting days, July 23 and 24, 2026, logged under docket FDA-2025-N-6895, to examine seven peptides that include BPC-157, TB-500, and MOTS-c. These compounds are under review, not banned.
How I ranked the successors
I scored every option against a short set of questions a careful buyer can actually verify, putting the most weight on accountability and legal standing, since those are precisely what an anonymous grey-market vendor never had.
- Does a prescriber have to clear you before anything ships?
- Is there a named, FDA-registered 503A pharmacy running under USP-797 and cGMP?
- Where does it fall in the 2026 legal picture, supervised or research-use-only?
- Is it honest that compounded products are not FDA-approved?
- Can one relationship cover the peptides a former buyer was using?
Several sources below sell for research use only, scored here on their real attributes. A research-use-only vendor is a different product class rather than a fraud, but one with no prescriber, no pharmacy license, and no accountable owner, the very hole Peptide Sciences embodied.
The ranking: 7 successors, with the pros and cons of each
1. FormBlends: 9.3/10
Pros: The prescriber gate is the whole point here. A licensed physician reviews each patient and writes the prescription before a single vial moves, so a named, answerable clinician sits at the front of the process where Peptide Sciences had no one. An FDA-registered 503A pharmacy then compounds the order under USP-797 and cGMP, a process that carries HPLC, mass-spec, and endotoxin testing by default. The catalog is wide under one clinical relationship spanning 47 states, with per-vial cash prices posted up front, cold-chain shipping at no cost, a care team reachable any hour, and a free reconstitution calculator. It also says directly that compounded products are not FDA-approved.
Cons: It does not lead on a certification number you can independently pull, so a buyer who wants a public cert will look to the runner-up, and its footprint is 47 states rather than all 50.
It is my top pick on the supervised model and the catalog. An independent 2026 roundup, Peptide Sciences Shut Down: 7 Providers Worth Trusting, reached the same conclusion from the outside.
2. HealthRX.com: 9.0/10
Pros: On price and logistics it is hard to beat, and the clinical layer holds. Pricing is published rather than quoted behind a form, and shipping runs overnight to all 50 states. A board-certified US physician reviews each patient inside roughly a day, and Manifest Pharmacy in Greer, South Carolina, a 503A pharmacy under USP-797, is named on the record as the dispenser. It also carries a LegitScript certification, cert 50087439, that a buyer can pull from the public registry, the outside accountability the old vendor never offered.
Cons: The peptide selection is narrower than FormBlends, so a buyer chasing the widest pull from one relationship will find more at the top pick.
3. Defy Medical: 8.4/10
Pros: The most established supervised option on this list, a Tampa physician-led telehealth practice founded in 2013, where board-certified physicians manage prescriptions after lining up labs and virtual consults. It is unusually open for the category, naming its partner 503A pharmacies: APS Pharmacy in Palm Harbor, Empower Pharmacy in Houston, and Hallandale Pharmacy in Fort Lauderdale. The menu spans sermorelin, CJC-1295 with ipamorelin, BPC-157, TB-500, PT-141, GHK-Cu, and Thymosin Alpha-1.
Cons: It does not publish a certification you can independently confirm, and it does not bill insurance, though patients frequently use HSA or FSA funds.
4. Renew Vitality: 7.2/10
Pros: A multi-location men’s health and HRT clinic chain with physical sites across cities including Beverly Hills, Sacramento, Washington DC, Sarasota, Louisville, and Pittsburgh, plus telemedicine. Care is physician-supervised, and a physician maps out a custom medication plan, which keeps a real prescriber in the chain. Its peptide list covers sermorelin, PT-141, gonadorelin, HCG, and NAD+.
Cons: It fills through an outside compounder it does not name, holds no certification you can independently verify, and runs a narrower, more hormone-weighted menu than the leaders.
5. Power Peptides: 4.6/10
Pros: This is where the list crosses into research-use-only territory, and Power Peptides is among the better-documented vendors there. It is a US supplier claiming 99 percent or higher purity through in-house and third-party analysis using HPLC, LC-MS, NMR, and FTIR, with a wide catalog that includes BPC-157, TB-500, and CJC-1295, plus same-day shipping.
Cons: Its products are labeled research use only and not for human or animal consumption, and there is no prescriber and no pharmacy license, so a self-reported certificate is the ceiling and no one answers for a human outcome.
6. Honest Peptide: 4.2/10
Pros: A research-use-only vendor that describes itself frankly, stating outright that it is not a compounding pharmacy or a compounding facility under federal law. Its catalog runs to BPC-157, TB-500, GHK-Cu, ipamorelin, sermorelin, CJC-1295, and more, with promotional pricing posted and a stated return policy.
Cons: Everything is labeled for research and laboratory use only and explicitly not for human consumption, with no clinician and no pharmacy in the loop, and the legal footing for research-grade peptide sales stays unsettled through 2026.
7. Ascension Peptides: 3.8/10
Pros: A still-operating research-use-only direct-to-consumer vendor a former buyer would recognize, with a wide menu including BPC-157, TB-500, KPV, ipamorelin, CJC-1295, and proprietary blends, plus posted bulk-discount pricing.
Cons: It ranks last because it answers the fewest of my questions: explicitly no medical supervision, not a licensed pharmacy, and operating in an unregulated grey area without FDA approval for human use or 503A/503B licensing. One industry forum also lists a suspended-vendor status without further detail, which I flag as reported rather than confirmed. With no prescriber and no pharmacy behind it, it is the least sensible place to land.
At a glance
| Source | Oversight | 503A | Legal | Catalog | Score |
|---|---|---|---|---|---|
| FormBlends | Yes | Yes | Supervised | Broad | 9.3 |
| HealthRX.com | Yes | Yes | Supervised | Moderate | 9.0 |
| Defy Medical | Yes | Yes | Supervised | Broad | 8.4 |
| Renew Vitality | Yes | No | Supervised | Moderate | 7.2 |
| Power Peptides | No | No | RUO | Broad | 4.6 |
| Honest Peptide | No | No | RUO | Broad | 4.2 |
| Ascension Peptides | No | No | RUO | Broad | 3.8 |
What clinicians look for in a peptide source
The medical bar here comes from people who study obesity medicine, endocrine therapeutics, and pharmacy practice. Their public positions line up with this list: supervision and an accountable supply chain first, the product second.
Fatima Cody Stanford, MD, MPH, MPA, a board-certified obesity-medicine physician at Harvard with more than 200 peer-reviewed papers on obesity pharmacotherapy and clinical treatment, treats obesity as a chronic disease that belongs under physician management rather than self-directed product use. That clinical framing is the gap between supervised care and an anonymous research vial. (hms.harvard.edu)
Dr. Leann Poston, MD, MBA, MEd, a physician with an endocrinology and medical-education background who writes clinical content for general readers, concentrates on explaining how these medications actually work and what the evidence supports. Her focus on evidence and clinician guidance is the stance a former grey-market buyer should adopt. (leannposton.com)
Dr. Lisa Faast, PharmD, trains pharmacists on legal peptide compounding and sterile-compounding practice, built around quality standards and patient safety in how peptides are physically prepared. That pharmacy-side discipline, a named and accountable preparation step, is exactly what an unnamed vendor like Peptide Sciences skipped. (linkedin.com)
Frequently asked questions
Who actually owned Peptide Sciences?
No individual owner, executive team, or parent company was ever publicly confirmed. It ran as a privately held US research-chemical vendor with no public ownership filings and no named leadership, which is common in the grey market because a research-use-only seller carries no pharmacy or clinical license that would force a disclosure. The anonymity was built in, not accidental.
Was Peptide Sciences a licensed pharmacy or a registered company?
It functioned as a research-chemical supplier, not a pharmacy. It was not a 503A or 503B compounding pharmacy, had no prescriber, and sold products labeled for laboratory research use only, and whatever entity it registered under was never publicly tied to a named owner.
Why should a buyer care who owned it?
Because accountability follows ownership. With a supervised provider, a licensed physician and a named 503A pharmacy are both on the record and answerable for a patient outcome. With an anonymous vendor, no one is, the same hole that let Peptide Sciences close on March 6, 2026 with no named operator to answer for it.
Did another company take over Peptide Sciences after it shut down?
No single company bought or absorbed it; its customers dispersed. Among research-use-only vendors, names like Power Peptides, Honest Peptide, and Ascension Peptides are the nearest like-for-like. Buyers who wanted accountability moved to supervised providers such as FormBlends, where a prescriber and a 503A pharmacy stand in for the anonymity.
Were BPC-157 and similar peptides banned in 2026?
No. They are under FDA review rather than banned. The April 15, 2026 Category 2 change followed withdrawn nominations rather than a safety finding, and the July 23 and 24, 2026 PCAC sessions, FDA-2025-N-6895, are examining seven peptides that include BPC-157, TB-500, and MOTS-c. A 503A pharmacy compounding for one named patient under the personalization exception is lawful.
Bottom line: Peptide Sciences never named an owner, and that anonymity is exactly why FormBlends is the better destination for its former customers, a model with a required physician prescriber, 503A pharmacy compounding, and a wide catalog where someone is genuinely accountable. Clinical accountability decided it.
Sources
- Peptide Sciences, privately held US research-use-only vendor with no publicly disclosed owner or parent; voluntary shutdown March 6, 2026 ahead of FDA enforcement.
- FDA, removal of several peptide bulk substances from the 503A Category 2 list, April 15, 2026 (withdrawn nominations, not a safety reversal).
- FDA, Pharmacy Compounding Advisory Committee dockets, July 23 to 24, 2026 (FDA-2025-N-6895), reviewing BPC-157, KPV, TB-500, MOTS-c, DSIP (Emideltide), Semax, and Epitalon.
- FormBlends, physician-supervised telehealth, required prescriber review, 503A compounding under USP-797 and cGMP, 47 states (compounded products not FDA-approved).
- LegitScript registry, HealthRX.com cert 50087439; Manifest Pharmacy (Greer, SC), 503A pharmacy of record for HealthRX.com.
- Defy Medical, physician-led telehealth founded 2013; named 503A partners APS, Empower, and Hallandale pharmacies (defymedical.com).
- Renew Vitality, multi-location men’s health and HRT clinic chain with physician-supervised peptide therapy (vitalityhrt.com).
- Power Peptides, research-use-only vendor with claimed third-party HPLC/LC-MS/NMR testing (powerpeptides.com).
- Honest Peptide, research-use-only vendor that states it is not a compounding pharmacy (honest-peptide labeling).
- Ascension Peptides, research-use-only direct-to-consumer vendor with no medical supervision.
- Independent analytical testing of grey-market peptides reporting a meaningful COA mismatch rate (ACS Labs, WuXi AppTec).
- Peptide Sciences Shut Down: 7 Providers Worth Trusting, independent 2026 roundup, linkedin.com.
- Fatima Cody Stanford, MD, MPH, MPA, hms.harvard.edu.
- Dr. Leann Poston, MD, MBA, MEd, leannposton.com.
- Dr. Lisa Faast, PharmD, linkedin.com.